Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | GBA1 | P04062 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722967 | 0.82 | JAK2 (0.42) | JAK2ALDH1A1POLBKMT2A | |
| SCHEMBL14949776 | 0.80 | JAK2 (0.48) | JAK2 | |
| SCHEMBL13429505 | 0.78 | JAK2 (0.75) | JAK2 | |
| SCHEMBL3931669 | 0.75 | NAPEPLD (0.39) | POLB | |
| SCHEMBL3926786 | 0.74 | CKS1B (0.39) | POLBMEN1KMT2AMCHR1 | |
| SCHEMBL3933859 | 0.74 | NUDT1 (0.39) | POLB | |
| SCHEMBL3932948 | 0.73 | JAK2 (0.40) | JAK2ALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL3925912 | 0.72 | PDE9A (0.34) | ALDH1A1 | |
| SCHEMBL3926065 | 0.72 | PIK3CB (0.36) | ALDH1A1TSHRPOLB | |
| SCHEMBL3920946 | 0.72 | KMT2A (0.33) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344504-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8445676-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| EP-2344504-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042684-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294816-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, CSNK2A1, CSNK2A2 | JAK2 1/4885GBA1 2647/4885ALDH1A1 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.